Table 3.
Cardiovascular Outcome Trials With Glucagon Like Peptide-1 Receptor Agonists
| ELIXA | LEADER | SUSTAIN 6 | EXSCEL | HARMONY | REWIND | PIONEER-6 | |
|---|---|---|---|---|---|---|---|
| No. of patients | 6068 | 9340 | 3297 | 14,752 | 9463 | 9901 | 3183 |
| GLP-1 RA agent | Lixisenatide | Liraglutide | Semaglutide | Exenatide | Albiglutide | Dulaglutide | Semaglutide (oral) |
| Dosing | Daily | Daily | Weekly | Weekly | Weekly | Weekly | Daily |
| History of prior CVD | 100% | 81% | 83% | 73% | 100% | 31% | 85% (CVD or CKD) |
| Mean age (years) | 60 | 64 | 54 | 62 | 64 | 66 | 66 |
| Women | 30% | 36% | 39% | 38% | 31% | 46% | 32% |
| Median follow-up | 2.1 years | 3.8 years | 2.1 years | 3.2 years | 1.6 years | 5.4 years | 15.9 months |
| Diabetes duration (years) | 9.3 | 12.8 | 13.9 | 13.1y | 14.2y | 10.5 | 14.7 |
| Baseline A1c | 7.7% | 8.7% | 8.7% | 8.1% | 8.8% | 7.3% | 8.2% |
| Baseline eGFR (mL/min/1.73 m2) | 76 | ~75 | ~75 | 76 | 79 | 77 | 74 |
| UACR | Median 10.4 mg/g | Median ∼50 mg/g (eGFR<60 mL/min/1.73 m2) and ∼16 mg/g (eGFR ≥60 mL/min/1.73 m2) | N/A | N/A | N/A | 1.82 mg/g | N/A |
| SBP | 130 | 136 | 136 | 135 | 135 | 137 | 135 |
| DBP | N/A | 77 | 77 | 80 | 77 | 78 | 76 |
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); N/A, not available; RA, ; SBP, systolic blood pressure; UACR, albumin to creatinine ratio (mg/g).